ATRA
$14.99
Atara Biotherap
$.27
1.83%
ATRA
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.88)
Revenue:  $1.65 Mil
Tuesday
Aug 3
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ATRA reports earnings?
Beat
Meet
Miss

Where is ATRA's stock price going from here?
Up
Flat
Down
Stock chart of ATRA
Analysts
Summary of analysts' recommendations for ATRA
Score
Grade
Pivots
Resistance
$16.70
$16.03
$15.51

$14.84

Support
$14.32
$13.65
$13.13
Tweet
Growth
Description
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.
Peers
InterCeptVertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsUltragenyx PharmaceuticalZoetisBristol-Myers SquibbPfizerEli LillyMerck & Co.